USPTO serial 74169035
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
New York, NY
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joseph A. Calvaruso
JOSEPH A CALVARUSO MORGAN & FINNEGAN345 PARK AVENEW YORK, NY 10154UNITED STATES| Class | Description | Status | First use |
|---|---|---|---|
| 036 | global banking services, and global financial services; namely, providing information on foreign currencies, rendered to non-U.S. resident | ABANDONED | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 2, 1993 | ABN1 | ABANDONMENT - EXPRESS MAILED | — |
| Dec 28, 1992 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 22, 1992 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 28, 1992 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Apr 20, 1992 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 1992 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 20, 1992 | IUAF | USE AMENDMENT FILED | — |
| Oct 18, 1991 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 27, 1991 | DOCK | ASSIGNED TO EXAMINER | — |